Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

08.11.2019 | short review | Ausgabe 4/2020 Open Access

memo - Magazine of European Medical Oncology 4/2020

Molecular profiling in gastroesophageal cancer—clinical routine and future perspective

memo - Magazine of European Medical Oncology > Ausgabe 4/2020
MD Hannah Christina Puhr, MD, PhD Aysegül Ilhan-Mutlu
Wichtige Hinweise

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


Although several large clinical trials have been conducted in order to investigate targeted inhibition of several molecular pathways in gastric cancer, only a limited number of targeted therapies have been introduced in clinical routine. Besides scientific interest, international guidelines recommend investigation of some distinct molecular alterations, which are associated with therapeutic consequences. These are (i) human epidermal growth factor receptor 2 (HER2), (ii) programmed death receptor 1 (PD-L1) and (iii) microsatellite instability (MSI). There are some emerging markers, such as Epstein–Barr virus (EBV), which might also be associated with a favorable response to immunotherapy. These routine and potential markers will be further discussed in the scope of this short review.

Unsere Produktempfehlungen

Abo für kostenpflichtige Inhalte

Über diesen Artikel

Weitere Artikel der Ausgabe 4/2020

memo - Magazine of European Medical Oncology 4/2020 Zur Ausgabe